(Q38748910)

6 September 2017

title

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions (English)

1 reference

6 September 2017

Tilman Schlothauer

1

1 reference

6 September 2017

Sylvia Herter

2

1 reference

6 September 2017

Claudia Ferrara Koller

3

1 reference

6 September 2017

Sandra Grau-Richards

4

1 reference

6 September 2017

Virginie Steinhart

5

1 reference

6 September 2017

Christian Spick

6

1 reference

6 September 2017

Manfred Kubbies

7

1 reference

6 September 2017

Christian Klein

8

1 reference

6 September 2017

Pablo Umaña

9

1 reference

6 September 2017

Ekkehard Mössner

10

1 reference

6 September 2017

publication date

29 August 2016

1 reference

Protein Engineering Design and Selection

6 September 2017

published in

1 reference

6 September 2017

volume

29

1 reference

6 September 2017

issue

10

1 reference

6 September 2017

page(s)

457-466

1 reference

IgG2m4, an engineered antibody isotype with reduced Fc function

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

A medicinal chemist's guide to molecular interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Hepatocyte clearance and pharmacokinetics of recombinant factor IX glycosylation variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Therapeutic antibodies for autoimmunity and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Modulation of antibody effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

The carbohydrate at FcgammaRIIIa Asn-162. An element required for high affinity binding to non-fucosylated IgG glycoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Structure of the Fc fragment of human IgE bound to its high-affinity receptor Fc epsilonRI alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

The IgG Fc receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Fc receptor-targeted therapies for the treatment of inflammation, cancer and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Isotype and glycoform selection for antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Interaction sites on human IgG-Fc for FcgammaR: current models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Structural basis for binding of human IgG1 to its high-affinity human receptor FcγRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Effects of altered FcγR binding on antibody pharmacokinetics in cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Structure of FcγRI in complex with Fc reveals the importance of glycan recognition for high-affinity IgG binding.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Multiple binding sites on the CH2 domain of IgG for mouse Fc gamma R11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Analyzing antibody-Fc-receptor interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Fcgamma receptors: old friends and new family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Structural characterization of a human Fc fragment engineered for lack of effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

The structure of a human type III Fcgamma receptor in complex with Fc

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

IgG binding sites on human Fc gamma receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Human antibody-Fc receptor interactions illuminated by crystal structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Platelet activation by CD9 monoclonal antibodies is mediated by the Fc gamma II receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

Activating and inhibitory Fcγ receptors in immunotherapy: being the actor or being the target

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FPROTEIN%2FGZW040

21 January 2018

Identifiers

DOI

10.1093/PROTEIN/GZW040

1 reference

6 September 2017

1 reference